SAFE-BioPharma Elects Four Pharma Executives to Board of Directors Business Wire FT. LEE, N.J. -- August 13, 2013 Four pharmaceutical executives have been elected to the Board of Directors of SAFE-BioPharma Association, the strategic non-profit collaboration that developed and manages the global SAFE-BioPharma® digital identity and digital signature standard for the life science and healthcare sectors. The association’s members include most of the world’s largest biopharmaceutical companies. The SAFE-BioPharma standard is used throughout the biopharmaceutical and healthcare industries to manage high assurance digital identities and to apply legally-binding digital signatures to electronic documents. The four new directors are: *James DeZazzo, Ph.D., Esq., Corporate IP Counsel, Dart NeuroScience, San Diego. Dr. DeZazzo earned his Ph.D. in Cellular Biology from the University of Michigan and his J.D. from Wayne State University. A registered patent attorney at the United States Patent and Trademark Office, he brings a multi-disciplinary perspective spanning more than 20 years of scientific research and nearly a decade of legal experience in law firm and industry settings. *Colleen McMahon, Head, Information Security Strategy, Governance and Architecture, GlaxoSmithKline, Philadelphia. Ms. McMahon participated in the original development of the SAFE-BioPharma standard and is responsible for the development of the GSK information protection strategy. *Hisashi Shimobayashi,Senior Director of Strategy and Planning,Information Systems, Astellas Pharma Inc., Tokyo. Mr. Shimobayashi is theGlobal Head for all IS strategy and planning. He has led Astellas global efforts to utilize the SAFE-BioPharma digital identity and signature standard. *Karan Sorensen, President,Sorensen Strategies, LLC, Charleston, SC, a strategic management consulting firm. Prior to forming Sorensen Strategies, Ms. Sorensen held several senior R&D/IT positions at Johnson & Johnson, including Vice President and Chief Information Officer Johnson & Johnson Pharmaceutical Research & Development LLC and Centocor Research & Development, Inc. The all-volunteer Board participates in establishing the association’s goals, which include global expansion of the SAFE-BioPharma standard among biopharmaceutical industry partners and the U.S. healthcare system and its acceptance by governments and research institutions. “Each of the new directors, brings specific talents to SAFE-BioPharma. They will complement our longer serving board members in providing effective governance of the standard,” said Mollie Shields-Uehling, president and CEO and a director of SAFE-BioPharma Association. About SAFE-BioPharma For more information on the SAFE-BioPharma standard for digital identity and digital signatures used in life science and healthcare settings, visit http://www.safe-biopharma.org. SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association. Contact: SAFE-BioPharma Association Jon Weisberg, 801-359-9977 Mobile: 801-860-9977 Jon.firstname.lastname@example.org
SAFE-BioPharma Elects Four Pharma Executives to Board of Directors
Press spacebar to pause and continue. Press esc to stop.